Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
The question of whether UK oncologists follow current anthracycline dose modifications when treating patients with liver dysfunction was addressed through a questionnaire. Oncologists were asked the dose of doxorubicin or epirubicin they would prescribe for a woman with breast cancer and liver metastases who had one of four different patterns of abnormal liver chemistry. In each case, the median dose of anthracycline that would have been prescribed was close to that currently recommended. There was, however, wide variation in the dose that oncologists said they would prescribe, some avoiding an anthracycline altogether, whereas others would give full-dose treatment. Medical oncologists would prescribe a significantly lower dose of anthracycline than clinical oncologists for a patient with the most severely disturbed liver tests. Overall, medical oncologists were also significantly more likely to prescribe epirubicin. These results show the need for new, widely accepted anthracycline dose modifications for patients with liver dysfunction.
Dobbs
N A
NA
Imperial Cancer Research Fund Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK.
Twelves
C J
CJ
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D019538:Health Care Surveys; D006801:Humans; D008107:Liver Diseases; D008495:Medical Oncology / Q000592:standards*; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires; D006113:United Kingdom
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin